Vita Life Sciences's book value per share for the quarter that ended in Dec. 2025 was A$1.01.
During the past 12 months, Vita Life Sciences's average Book Value Per Share Growth Rate was 9.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vita Life Sciences was 46.70% per year. The lowest was -0.60% per year. And the median was 17.60% per year.
Vita Life Sciences's current price is A$2.50. Its book value per share for the quarter that ended in Dec. 2025 was A$1.01. Hence, today's PB Ratio of Vita Life Sciences is 2.47.
During the past 13 years, the highest P/B Ratio of Vita Life Sciences was 4.67. The lowest was 1.33. And the median was 2.42.
Vita Life Sciences (ASX:VLS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Vita Life Sciences Book Value per Share Related Terms
Vita Life Sciences Book Value per Share Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VLS vs ZTS, UTHR: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Book Value per Share of A$1.01 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Vita Life Sciences and its competitors.
Is Vita Life Sciences' Book Value per Share too high?
Vita Life Sciences' current Book Value per Share is A$1.01. Overall, Vita Life Sciences has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Book Value per Share compare to ZTS and UTHR?
Vita Life Sciences' Book Value per Share of A$1.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Vita Life Sciences and its competitors. Vita Life Sciences's current Book Value per Share is A$1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current Book Value per Share is A$1.01. Vita Life Sciences' overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Book Value per Share is A$1.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Book Value per Share: A$1.01
GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
87GF Score
Get the complete analysis for ASX:VLS
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
